Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Krems An Der Donau – page 12

141 clinical trials in Krems An Der Donau, Austria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Krems An Der Donau at a glance
141
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

141 trials in Krems An Der Donau

Open in trial search

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Malignant melanoma

Not recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Ampreloxetine and Midodrine Hydrochloride for Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ampreloxetine
  • Sponsor:Theravance Biopharma Ireland Limited

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Plasma cell myeloma

Not recruiting

Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Isatuximab
  • Sponsor:Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH

Study on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase for Patients with Dupuytren's Contracture

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vibrio Alginolyticus Collagenase
  • Sponsor:Fidia Farmaceutici S.p.A.

Plasma cell myeloma

Not recruiting

Study on Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universitaetsklinikum Wuerzburg AöR

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Krems An Der Donau

What the registry says about research in the country

01 Oncology - Blood Cancers

Groundbreaking research focusing on multiple myeloma treatments, including studies of novel drug combinations and maintenance therapies following stem cell transplantation. These trials aim to improve patient outcomes through targeted therapeutic approaches.

  • Newly Diagnosed Multiple Myeloma
  • Relapsed/Refractory Multiple Myeloma
  • Follicular Lymphoma

Innovative treatment combinations involving drugs like teclistamab, lenalidomide, and elranatamab are being evaluated.

02 Respiratory Diseases

Clinical investigations centered on pulmonary fibrosis and related conditions, exploring new therapeutic options for patients with progressive lung diseases.

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Progressive Pulmonary Fibrosis
  • Interstitial Lung Disease

Studies focus on improving lung function and reducing disease progression through novel therapeutic agents.

03 Solid Tumors

Advanced research in treating various types of solid cancers, with particular emphasis on prostate cancer, breast cancer, and lung cancer.

  • Metastatic Prostate Cancer
  • Early-Stage Breast Cancer
  • Non-Small Cell Lung Cancer
  • Bladder Cancer

Trials evaluating targeted therapies and immunotherapy combinations for better treatment outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.